Prognostic role of preoperative carcinoembryonic antigen level in part-solid lung adenocarcinoma

Abstract

Background

Part-solid lung adenocarcinoma appears as a heterogeneous subgroup, and its surgical management is controversial. This study aimed to elucidate whether preoperative carcinoembryonic antigen, a time-honored tumor marker, can be used as a prognostic factor that contributes to its management.

Methods

We retrospectively reviewed consecutive patients with clinical-T1a-cN0M0 part-solid adenocarcinoma who underwent surgical resection between January 2011 and December 2015 at two institutions.

Results

Overall, 288 patients were identified. The median age was 69 years with 176 patients (61%) being female. The median follow-up time was 5.6 years. Lymph node metastases were found in 6 (15%) of 41 patients with elevated carcinoembryonic antigen levels, while 10 (4.0%) of 247 patients had normal carcinoembryonic antigen levels (P = 0.016). The 5-year overall survival rates in patients with normal and elevated carcinoembryonic antigen levels were 96.9% and 87.2%, respectively (P = 0.006), and the 5-year relapse-free survival rates were 91.8% and 62.8%, respectively (P < 0.001). The multivariable analysis revealed that preoperative carcinoembryonic antigen level was a significant prognostic factor for relapse-free survival (hazard ratio [HR] = 2.92, 95% confidence interval [CI] = 1.63–5.25, P < 0.001). Among the patients with elevated carcinoembryonic antigen levels, the 5-year overall survival rates in those undergoing lobar resection and segmentectomy were 87.0% and 88.9%, respectively (P = 0.59), and the 5-year relapse-free survival rates were 61.7% and 66.7%, respectively (P = 0.84).

Conclusions

Our data suggest that preoperative carcinoembryonic antigen level appears to be an important predictor of postoperative survival outcomes in early-stage part-solid adenocarcinoma. Further studies are required to optimize management of patients with elevated preoperative carcinoembryonic antigen levels, although segmentectomy appeared acceptable in those patients.

Keywords

Part-solid adenocarcinoma carcinoembryonic antigen non-small cell lung cancer segmentectomy prognostic factors

Get full access to this article

View all access options for this article.

References

Ettinger

Wood

Aisner

, et al. Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2017; 15: 504–535.

Postmus

Kerr

Oudkerk

, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28: iv1–iv21.

Zhang

Wen

, et al. Distinct prognostic factors in patients with stage I non-small cell lung cancer with radiologic part-solid or solid lesions. J Thorac Oncol 2019; 14: 2133–2142.

Hattori

Suzuki

Takamochi

, et al. Prognostic impact of a ground-glass opacity component in clinical stage IA non-small cell lung cancer. J Thorac Cardiovasc Surg 2020; 161: 1469–1480.

Matsunaga

Suzuki

Takamochi

, et al. What is the radiological definition of part-solid tumour in lung cancer?. Eur J Cardiothorac Surg 2017; 51: 242–247.

Hattori

Matsunaga

Takamochi

, et al. Significance of lymphadenectomy in part-solid lung adenocarcinoma: propensity score matched analysis. Ann Thorac Surg 2018; 106: 989–997.

Lee

Jeon

Jung

, et al. Predictive factors for lymph node metastasis in clinical stage I part-solid lung adenocarcinoma. Ann Thorac Surg 2020; 111: 456–462.

Sun

Zou

, et al. Analysis of segmental lymph node metastasis and clinical features in cT1N0M0 lung adenocarcinoma. Biomed Res Int 2020; 2020: 2842604.

Hattori

Hirayama

Matsunaga

, et al. Distinct clinicopathologic characteristics and prognosis based on the presence of ground glass opacity component in clinical stage IA lung adenocarcinoma. J Thorac Oncol 2019; 14: 265–275.

10.

Łochowski

Łochowska

Zawadzka

, et al. Prognostic value of neutrophil-to-lymphocyte, platelet-to-lymphocyte and lymphocyte-to-monocyte ratio ratios in patients operated on due to non-small cell lung cancer. J Thorac Dis 2019; 11: 3377–3384.

11.

Asamura

Hishida

Suzuki

, et al. Radiographically determined noninvasive adenocarcinoma of the lung: survival outcomes of Japan clinical oncology group 0201. J Thorac Cardiovasc Surg 2013; 146: 24–30.

12.

Fletcher

. Carcinoembryonic antigen. Ann Intern Med 1986; 104: 66–73.

13.

Grunnet

Sorensen

. Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer 2012; 76: 138–143.

14.

Huang

Chen

Huang

, et al. Prognostic value of postoperative serum carcinoembryonic antigen levels in colorectal cancer patients who smoke. PLoS One 2020; 15: e0233687.

15.

Taioli

Yip

Olkin

, et al. Survival after sublobar resection for early-stage lung cancer: methodological obstacles in comparing the efficacy to lobectomy. J Thorac Oncol 2016; 11: 400–406.

16.

Nakazawa

Shimizu

Mogi

, et al. VATS segmentectomy: past, present, and future. Gen Thorac Cardiovasc Surg 2018; 66: 81–90.

17.

Razi

Nguyen

Villamizar

. Lobectomy does not confer survival advantage over segmentectomy for non-small cell lung cancer with unsuspected nodal disease. J Thorac Cardiovasc Surg 2020; 159: 2469–2483.

18.

Cheng

Wang

, et al. A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer. Lung Cancer 2019; 137: 7–13.

19.

Yoshioka

Shimokawa

Seto

, et al. Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer. Ann Oncol 2019; 30: 1978–1984.

20.

Wang

, et al. The suitability of small biopsy and cytology specimens for EGFR and other mutation testing in non-small cell lung cancer. Transl Lung Cancer Res 2015; 4: 119–125.